title: Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections.
authors.affiliation: Pfizer Global Research and Development, Groton, Connecticut 06340, USA. steven.j.brickner@pfizer.com
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Brickner
authors.forename: Michael R
authors.initials: MR
authors.lastname: Barbachyn
authors.forename: Douglas K
authors.initials: DK
authors.lastname: Hutchinson
authors.forename: Peter R
authors.initials: PR
authors.lastname: Manninen
mesh_terms: D000081:Acetamides / Q000737:chemistry / Q000145:classification* / Q000627:therapeutic use*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000145:classification* / Q000627:therapeutic use*; D024881:Drug Resistance, Bacterial; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D000069349:Linezolid; D008826:Microbial Sensitivity Tests; D015394:Molecular Structure; D023303:Oxazolidinones / Q000737:chemistry / Q000145:classification* / Q000627:therapeutic use*
chemical_list: D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D000069349:Linezolid